Ce numéro du JAMC présente une critique systématique (page 725) portant sur l'utilisation,
chez les patients aux soins intensifs, de l'érythropoïétine, médicament dont on fait la …

This issue of CMAJ features a systematic review (page 725) of the use in critically ill patients
of erythropoietin, a drug that is widely promoted without an approved indication in this …

The meta-analysis by Zarychanski and colleagues suggests an overall reduction in the
proportion of patients who received transfusions in the erythropoietin group. However, given …

We read with interest Lasocki et al.'s letter [1]. We agree with many points, especially their
call for further research into the clinical effects of erythropoietin (EPO) in critically ill patients …

Background Anaemia is a common problem experienced by critically‐ill people. Treatment
with erythropoiesis‐stimulating agents (ESAs) has been used as a pharmacologic strategy …

Abstract Purpose Erythropoiesis stimulating agents (ESAs) are used to treat anemia in
critically ill patients. This indication is off-label, because it is not licensed by regulatory …

In critically ill patients, the use of recombinant human erythropoietin, rHuEPO, and other
erythropoiesis-stimulating agents (ESAs) has been advocated for the management of …

REDUCING THE FREQUENCY OF RED BLOOD CELL TRANS-fusion is a goal of modern
blood management. The primary driving force during the past 15 years has been safety. In …

L'insuffisance rénale chronique est une pathologie dont l'incidence a fortement augmenté
lors des dernières décennies. Cette croissance est en lien avec l'allongement de …

In patients with chronic kidney disease receiving regular treatment with recombinant
erythropoietins (rHuEPO or epoetins), infection and inflammation may lead to erythropoietin …